Clear Trail Advisors LLC Acquires Shares of 44,612 Medtronic PLC $MDT

Clear Trail Advisors LLC purchased a new position in shares of Medtronic PLC (NYSE:MDT) in the 4th quarter, Holdings Channel reports. The firm purchased 44,612 shares of the medical technology company’s stock, valued at approximately $4,285,000. Medtronic makes up approximately 1.0% of Clear Trail Advisors LLC’s investment portfolio, making the stock its 29th biggest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in MDT. Delos Wealth Advisors LLC acquired a new stake in shares of Medtronic in the second quarter valued at about $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic during the 3rd quarter valued at $27,000. Valley Wealth Managers Inc. bought a new position in shares of Medtronic during the 3rd quarter worth about $29,000. Board of the Pension Protection Fund acquired a new stake in Medtronic in the 4th quarter valued at $29,000. Finally, GoalVest Advisory LLC bought a new position in shares of Medtronic in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of MDT stock opened at $87.24 on Tuesday. The firm has a market capitalization of $112.01 billion, a price-to-earnings ratio of 24.30, a PEG ratio of 2.21 and a beta of 0.71. The stock has a fifty day moving average of $96.63 and a 200 day moving average of $96.69. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a $0.71 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. Medtronic’s payout ratio is 79.11%.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Citigroup assumed coverage on Medtronic in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price objective on the stock. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. UBS Group reaffirmed a “neutral” rating and set a $104.00 price objective on shares of Medtronic in a research note on Wednesday, February 4th. Leerink Partners restated an “outperform” rating and issued a $119.00 target price on shares of Medtronic in a research note on Tuesday, March 10th. Finally, Wells Fargo & Company assumed coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Insider Transactions at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).